Influenza virus vaccine

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

1 month ago talkbio0Tagged BioNTech, BioNTech acquisition, COVID19 (disease), CureVac, global framework, Influenza virus vaccine, Licensing, Litigation, Pfizer, RNA, Messenger, royalties, settlement, SmithKline Beecham, U.S., upfront payment, Vaccines, Vaccines, Combined

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

RFK Jr.’s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

3 months ago talkbio0Tagged ACIP, Advisory Committees, anti-vaccine movement, Centers for Disease Control and Prevention (U.S.), Immunization, Influenza virus vaccine, Policy, Practice Experience, Respiratory syncytial virus, RFK Jr., thimerosal, Vaccines

RFK Jr.; ACIP; thimerosal; flu vaccine; vaccine policy; anti-vaccine movement; CDC; RSV shot; Advisory Committee on Immunization Practices

Enhancing Flu Vaccine Manufacturing and Supply: A Comprehensive Overview

1 year ago talkbio0Tagged Influenza virus vaccine, Manufacture, pandemic preparedness, production, Supply Chain Reliability, Technology, Vaccines

Flu Vaccine Manufacturing, Supply Chain Reliability, Influenza Vaccine Production, Vaccine Manufacturing Technologies, Pandemic Preparedness